1. Szamatowicz M, Szamatowicz J. Proven and unproven
methods for diagnosis and treatment of infertility. Adv Med
Sci. 2020;65(1):93-6. doi: 10.1016/j.advms.2019.12.008.
2. Starc A, Trampuš M, Pavan Jukić D, Rotim C, Jukić T, Polona
Mivšek A. Infertility and sexual dysfunctions: a systematic
literature review. Acta Clin Croat. 2019;58(3):508-15. doi:
10.20471/acc.2019.58.03.15.
3. Onat G, Beji NK. Marital relationship and quality of life
among couples with infertility. Sex Disabil. 2012;30(1):39-52.
doi: 10.1007/s11195-011-9233-5.
4. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher
AD, et al. Risk factors for sexual dysfunction among women
and men: a consensus statement from the Fourth International
Consultation on Sexual Medicine 2015. J Sex Med.
2016;13(2):153-67. doi: 10.1016/j.jsxm.2015.12.015.
5. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang
H, et al. Epidemiology of DSM-5 alcohol use disorder: results
from the National Epidemiologic Survey on Alcohol and
Related Conditions III. JAMA Psychiatry. 2015;72(8):757-66.
doi: 10.1001/jamapsychiatry.2015.0584.
6. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J,
et al. Epidemiology of DSM-5 drug use disorder: results from
the National Epidemiologic Survey on Alcohol and Related
Conditions-III. JAMA Psychiatry. 2016;73(1):39-47. doi:
10.1001/jamapsychiatry.2015.2132.
7. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug
use: 2017 status report. Addiction. 2018;113(10):1905-26.
doi: 10.1111/add.14234.
8. Shalbafan M, Donboli S, Salehian R. Effect of variable
substances on sexual function: a narrative review. J Iran Med
Council. 2019;2(5):112-9.
9. George WH. Alcohol and sexual health behavior: “what we
know and how we know it”. J Sex Res. 2019;56(4-5):409-24.
doi: 10.1080/00224499.2019.1588213.
10. Ghadigaonkar DS, Murthy P. Sexual dysfunction in persons
with substance use disorders. J Psychosexual Health.
2019;1(2):117-21. doi: 10.1177/2631831819849365.
11. Ryan KS, Bash JC, Hanna CB, Hedges JC, Lo JO. Effects of
marijuana on reproductive health: preconception and
gestational effects. Curr Opin Endocrinol Diabetes Obes.
2021;28(6):558-65. doi: 10.1097/med.0000000000000686.
12. Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction
in men and women. Aust Prescr. 2013;36(2):42-5. doi:
10.18773/austprescr.2013.021.
13. Ghosh A, Kathiravan S, Sharma K, Mattoo SK. A scoping review
of the prevalence and correlates of sexual dysfunction in adults
with substance use disorders. J Sex Med. 2022;19(2):216-33.
doi: 10.1016/j.jsxm.2021.11.018.
14. Hosseinzadeh Zoroufchi B, Doustmohammadi H, Mokhtari T,
Abdollahpour A. Benzodiazepines related sexual dysfunctions: a
critical review on pharmacology and mechanism of action. Rev
Int Androl. 2021;19(1):62-8. doi: 10.1016/j.androl.2019.08.003.
15. Sadock BJ, Sadock VA, Ruiz P. Comprehensive Textbook
of Psychiatry. 10th ed. United States of America: Wolters
Kluwer; 2017.
16. Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The
effects of opioids and opioid analogs on animal and human
endocrine systems. Endocr Rev. 2010;31(1):98-132. doi:
10.1210/er.2009-0009.
17. Antony T, Alzaharani SY, El-Ghaiesh SH. Opioid-induced
hypogonadism: pathophysiology, clinical and therapeutics
review. Clin Exp Pharmacol Physiol. 2020;47(5):741-50. doi:
10.1111/1440-1681.13246.
18. Buffum J. Pharmacosexology: the effects of drugs on sexual
function a review. J Psychoactive Drugs. 1982;14(1-2):5-44.
doi: 10.1080/02791072.1982.10471907.
19. Yilmaz MO, Akin Y, Gulum M, Ciftci H, Yeni E. Relationship
between smoking and female sexual dysfunction. Andrology
(Los Angel). 2015;4(2):144. doi: 10.4172/2167-0250.1000144.
20. Bhattacharyya R, Sanyal D, Bhattacharyya S, Chakraborty
K, Neogi R, Banerjee BB. Depression, sexual dysfunction,
and medical comorbidities in young adults having nicotine
dependence. Indian J Community Med. 2020;45(3):295-8.
doi: 10.4103/ijcm.IJCM_153_19.
21. Hirshkowitz M, Karacan I, Howell JW, Arcasoy MO, Williams
RL. Nocturnal penile tumescence in cigarette smokers
with erectile dysfunction. Urology. 1992;39(2):101-7. doi:
10.1016/0090-4295(92)90263-v.
22. Rawson RA, Washton A, Domier CP, Reiber C. Drugs and
sexual effects: role of drug type and gender. J Subst Abuse Treat.
2002;22(2):103-8. doi: 10.1016/s0740-5472(01)00215-x.
23. Weatherby NL, Shultz JM, Chitwood DD, McCoy HV, McCoy
CB, Ludwig DD, et al. Crack cocaine use and sexual activity
in Miami, Florida. J Psychoactive Drugs. 1992;24(4):373-80.
doi: 10.1080/02791072.1992.10471661.
24. Cocores JA, Miller NS, Pottash AC, Gold MS. Sexual dysfunction
in abusers of cocaine and alcohol. Am J Drug Alcohol Abuse.
1988;14(2):169-73. doi: 10.3109/00952999809001544.
25. Volkow ND, Michaelides M, Baler R. The neuroscience of
drug reward and addiction. Physiol Rev. 2019;99(4):2115-40.
doi: 10.1152/physrev.00014.2018.
26. Mireku-Boateng AO, Tasie B. Priapism associated with
intracavernosal injection of cocaine. Urol Int. 2001;67(1):109-
10. doi: 10.1159/000050961.
27. Chamberlain SR, Lust K, Grant JE. Cocaine use in university
students: relationships with demographics, mental health,
risky sexual practices, and trait impulsivity. CNS Spectr.
2021;26(5):501-8. doi: 10.1017/s1092852920001492.
28. Käll KI. Effects of amphetamine on sexual behavior of male
i.v. drug users in Stockholm--a pilot study. AIDS Educ Prev.
1992;4(1):6-17.
29. Russell K, Dryden DM, Liang Y, Friesen C, O’Gorman K,
Durec T, et al. Risk factors for methamphetamine use in
youth: a systematic review. BMC Pediatr. 2008;8:48. doi:
10.1186/1471-2431-8-48.
30. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse.
Am Fam Physician. 2007;76(8):1169-74.
31. Hirshfield S, Remien RH, Walavalkar I, Chiasson MA. Crystal
methamphetamine use predicts incident STD infection among
men who have sex with men recruited online: a nested
case-control study. J Med Internet Res. 2004;6(4):e41. doi:
10.2196/jmir.6.4.e41.
32. Angst J. Sexual problems in healthy and depressed persons.
Int Clin Psychopharmacol. 1998;13 Suppl 6:S1-4. doi:
10.1097/00004850-199807006-00001.
33. Dubin NN, Razack AH. Priapism: ecstasy related? Urology.
2000;56(6):1057. doi: 10.1016/s0090-4295(00)00839-6.
34. Tran QT, Wallace RA, Sim EH. Priapism, ecstasy, and marijuana:
is there a connection? Adv Urol. 2008;2008:193694. doi:
10.1155/2008/193694.
35. Kumsar NA, Kumsar Ş, Dilbaz N. Sexual dysfunction in
men diagnosed as substance use disorder. Andrologia.
2016;48(10):1229-35. doi: 10.1111/and.12566.
36. Graf H, Malejko K, Metzger CD, Walter M, Grön G, Abler B.
Serotonergic, dopaminergic, and noradrenergic modulation
of erotic stimulus processing in the male human brain. J Clin
Med. 2019;8(3):363. doi: 10.3390/jcm8030363.
37. Basson R, Gilks T. Women’s sexual dysfunction associated with
psychiatric disorders and their treatment. Womens Health (Lond).
2018;14:1745506518762664. doi: 10.1177/1745506518762664.
38. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An
update. Drug Saf. 1993;8(6):414-26. doi: 10.2165/00002018-
199308060-00003.
39. Mutha AS, Kulkarni VR, Beldar AS, Patel SB. Use of neuropsychiatry
medicines in patients with sexual dysfunction: a
retrospective study. Int J Basic Clin Pharmacol. 2017;6(3):563-
7. doi: 10.18203/2319-2003.ijbcp20170813.
40. Pominville R, Loria M, Fraiman E, Mishra K. Sexual dysfunction
related to ketamine use: a systematic review. Curr Sex Health
Rep. 2023;15(3):125-31. doi: 10.1007/s11930-023-00363-0.
41. Chew KK, Bremner A, Stuckey B, Earle C, Jamrozik K. Alcohol
consumption and male erectile dysfunction: an unfounded
reputation for risk? J Sex Med. 2009;6(5):1386-94. doi:
10.1111/j.1743-6109.2008.01115.x.
42. Lianjun P, Aixia Z, Zhong W, Feng P, Li B, Xiaona Y. Risk
factors for low sexual function among urban Chinese women:
a hospital-based investigation. J Sex Med. 2011;8(8):2299-
304. doi: 10.1111/j.1743-6109.2011.02313.x.
43. Anil Kumar BN, Shalini M, Prasannakumar DR. Sexual
dysfunction in women with alcohol dependence syndrome:
a study from India. Asian J Psychiatr. 2017;28:9-14. doi:
10.1016/j.ajp.2017.03.007.
44. de Angelis C, Nardone A, Garifalos F, Pivonello C, Sansone
A, Conforti A, et al. Smoke, alcohol and drug addiction and
female fertility. Reprod Biol Endocrinol. 2020;18(1):21. doi:
10.1186/s12958-020-0567-7.
45. Dissiz M. Evaluation of sexual function in Turkish male individuals who are substance abusers: a descriptive study.
Addict Disord Their Treat. 2019;18(3):176-83. doi: 10.1097/
adt.0000000000000172.
46. National Institute on Drug Abuse (NIDA). Drugs, Brains, and
Behavior: The Science of Addiction. North Bethesda: NIDA; 2014.
47. Zaazaa A, Bella AJ, Shamloul R. Drug addiction and
sexual dysfunction. Endocrinol Metab Clin North Am.
2013;42(3):585-92. doi: 10.1016/j.ecl.2013.06.003.
48. Guha M. Diagnostic and statistical manual of mental disorders:
DSM-5 (5th edition). Reference Reviews. 2014;28(3):36-7.
doi: 10.1108/rr-10-2013-0256.
49. American Psychiatric Association (APA). Diagnostic and
Statistical Manual of Mental Disorders. 5th ed. Washington,
DC: APA; 2013. p. 591-643.
50. Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L,
Vanderschuren L. Addiction as a brain disease revised:
why it still matters, and the need for consilience.
Neuropsychopharmacology. 2021;46(10):1715-23. doi:
10.1038/s41386-020-00950-y.
51. Substance Abuse and Mental Health Services Administration
(SAMHSA). Treating Concurrent Substance Use Among
Adults. Rockville, MD: SAMHSA; 2021.
52. McHugh RK, Hearon BA, Otto MW. Cognitive behavioral
therapy for substance use disorders. Psychiatr Clin North Am.
2010;33(3):511-25. doi: 10.1016/j.psc.2010.04.012.
53. Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM,
Magill M. Combined pharmacotherapy and cognitive
behavioral therapy for adults with alcohol or substance
use disorders: a systematic review and meta-analysis.
JAMA Netw Open. 2020;3(6):e208279. doi: 10.1001/
jamanetworkopen.2020.8279.
54. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects
of female sexual dysfunction. J Sex Med. 2004;1(1):82-6. doi:
10.1111/j.1743-6109.2004.10112.x.
55. Kammerer-Doak D, Rogers RG. Female sexual function and
dysfunction. Obstet Gynecol Clin North Am. 2008;35(2):169-
83. doi: 10.1016/j.ogc.2008.03.006.
56. Mykletun A, Dahl AA, O’Leary MP, Fosså SD. Assessment
of male sexual function by the Brief Sexual Function
Inventory. BJU Int. 2006;97(2):316-23. doi: 10.1111/j.1464-
410X.2005.05904.x.
57. Woodard TL, Diamond MP. Physiologic measures of sexual
function in women: a review. Fertil Steril. 2009;92(1):19-34.
doi: 10.1016/j.fertnstert.2008.04.041.
58. Park K, Goldstein I, Andry C, Siroky MB, Krane RJ, Azadzoi KM.
Vasculogenic female sexual dysfunction: the hemodynamic
basis for vaginal engorgement insufficiency and clitoral
erectile insufficiency. Int J Impot Res. 1997;9(1):27-37. doi:
10.1038/sj.ijir.3900258.
59. Clement P, Giuliano F. Anatomy and physiology of genital
organs - men. Handb Clin Neurol. 2015;130:19-37. doi:
10.1016/b978-0-444-63247-0.00003-1.
60. Goldstein I, Clayton AH, Goldstein AT, Kim NN, Kingsberg
SA. Textbook of Female Sexual Function and Dysfunction:
Diagnosis and Treatment. John Wiley & Sons; 2018.
61. Moini J, LoGalbo A, Ahangari R. Chapter 23 - Substance abuse.
In: Moini J, LoGalbo A, Ahangari R, editors. Foundations of the
Mind, Brain, and Behavioral Relationships: Academic Press;
2024. p. 389-408. doi:10.1016/B978-0-323-95975-9.00008-
1.
62. Taylor JL, Samet JH. Opioid use disorder. Ann Intern Med.
2022;175(1):ITC1-16. doi: 10.7326/aitc202201180.
63. Wilson J, Freeman TP, Mackie CJ. Effects of increasing cannabis
potency on adolescent health. Lancet Child Adolesc Health.
2019;3(2):121-8. doi: 10.1016/s2352-4642(18)30342-0.
64. ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A.
Phytochemistry of Cannabis sativa L. Prog Chem Org Nat
Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1.
65. Pizzol D, Demurtas J, Stubbs B, Soysal P, Mason C, Isik
AT, et al. Relationship between cannabis use and erectile
dysfunction: a systematic review and meta-analysis. Am
J Mens Health. 2019;13(6):1557988319892464. doi:
10.1177/1557988319892464.
66. Moser A, Ballard SM, Jensen J, Averett P. The influence of
cannabis on sexual functioning and satisfaction. J Cannabis
Res. 2023;5(1):2. doi: 10.1186/s42238-022-00169-2.
67. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression
of plasma testosterone levels after chronic intensive marihuana
use. N Engl J Med. 1974;290(16):872-4. doi: 10.1056/
nejm197404182901602.
68. Thistle JE, Graubard BI, Braunlin M, Vesper H, Trabert B,
Cook MB, et al. Marijuana use and serum testosterone
concentrations among U.S. males. Andrology. 2017;5(4):732-
8. doi: 10.1111/andr.12358.
69. Dalterio S, Bartke A, Mayfield D. Delta9-tetrahydrocannabinol
increase plasma testosterone concentrations in mice. Science.
1981;213(4507):581-3. doi: 10.1126/science.6264607.
70. Benowitz NL. Nicotine addiction. Prim Care. 1999;26(3):611-
31. doi: 10.1016/s0095-4543(05)70120-2.
71. Benowitz NL. Nicotine addiction. N Engl J Med.
2010;362(24):2295-303. doi: 10.1056/NEJMra0809890.
72. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention
and treatment of opioid misuse and addiction: a review.
JAMA Psychiatry. 2019;76(2):208-16. doi: 10.1001/
jamapsychiatry.2018.3126.
73. MacNicol B. The biology of addiction. Can J Anaesth.
2017;64(2):141-8. doi: 10.1007/s12630-016-0771-2.
74. Dela Peña I, Gevorkiana R, Shi WX. Psychostimulants affect
dopamine transmission through both dopamine transporterdependent
and independent mechanisms. Eur J Pharmacol.
2015;764:562-70. doi: 10.1016/j.ejphar.2015.07.044.
75. Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM,
Young AH, et al. The dopamine hypothesis of bipolar affective
disorder: the state of the art and implications for treatment. Mol
Psychiatry. 2017;22(5):666-79. doi: 10.1038/mp.2017.16.
76. Warner EA. Cocaine abuse. Ann Intern Med. 1993;119(3):226-
35. doi: 10.7326/0003-4819-119-3-199308010-00009.
77. Maxwell JC. Emerging research on methamphetamine. Curr
Opin Psychiatry. 2005;18(3):235-42. doi: 10.1097/01.
yco.0000165592.52811.84.
78. Jansen KL, Theron L. Ecstasy (MDMA), methamphetamine,
and date rape (drug-facilitated sexual assault): a consideration
of the issues. J Psychoactive Drugs. 2006;38(1):1-12. doi:
10.1080/02791072.2006.10399822.
79. Bang-Ping J. Sexual dysfunction in men who abuse illicit
drugs: a preliminary report. J Sex Med. 2009;6(4):1072-80.
doi: 10.1111/j.1743-6109.2007.00707.x.
80. Gonzales R, Mooney L, Rawson RA. The methamphetamine
problem in the United States. Annu Rev Public Health. 2010;31:385-
98. doi: 10.1146/annurev.publhealth.012809.103600.
81. Fisher DG, Reynolds GL, Napper LE. Use of crystal
methamphetamine, Viagra, and sexual behavior. Curr Opin Infect
Dis. 2010;23(1):53-6. doi: 10.1097/QCO.0b013e328334de0b.
82. Semple SJ, Zians J, Grant I, Patterson TL. Sexual risk behavior
of HIV-positive methamphetamine-using men who have sex
with men: the role of partner serostatus and partner type. Arch
Sex Behav. 2006;35(4):461-71. doi: 10.1007/s10508-006-
9045-3.
83. Forrest DW, Metsch LR, LaLota M, Cardenas G, Beck DW,
Jeanty Y. Crystal methamphetamine use and sexual risk
behaviors among HIV-positive and HIV-negative men
who have sex with men in South Florida. J Urban Health. 2010;87(3):480-5. doi: 10.1007/s11524-009-9422-z.
84. Cyranowski JM, Bromberger J, Youk A, Matthews K, Kravitz
HM, Powell LH. Lifetime depression history and sexual
function in women at midlife. Arch Sex Behav. 2004;33(6):539-
48. doi: 10.1023/B:ASEB.0000044738.84813.3b.
85. Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL,
Rafi-Tari S. Sexual function during bupropion or paroxetine
treatment of major depressive disorder. Can J Psychiatry.
2006;51(4):234-42. doi: 10.1177/070674370605100405.
86. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F.
Incidence of sexual dysfunction associated with antidepressant
agents: a prospective multicenter study of 1022 outpatients.
Spanish Working Group for the Study of Psychotropic-Related
Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21.
87. Roberts CA, Jones A, Montgomery C. Meta-analysis of
executive functioning in ecstasy/polydrug users. Psychol Med.
2016;46(8):1581-96. doi: 10.1017/s0033291716000258.
88. Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin
D, Pope HG Jr. Residual neurocognitive features of longterm
ecstasy users with minimal exposure to other drugs.
Addiction. 2011;106(4):777-86. doi: 10.1111/j.1360-
0443.2010.03252.x.
89. McElrath K. MDMA and sexual behavior: ecstasy users’
perceptions about sexuality and sexual risk. Subst Use Misuse.
2005;40(9-10):1461-77. doi: 10.1081/ja-200066814.
90. May AL, Parrott AC. Greater sexual risk-taking in female and
male recreational MDMA/ecstasy users compared with alcohol
drinkers: a questionnaire study. Hum Psychopharmacol.
2015;30(4):272-5. doi: 10.1002/hup.2432.
91. Palamar JJ, Griffin-Tomas M, Acosta P, Ompad DC,
Cleland CM. A comparison of self-reported sexual effects
of alcohol, marijuana, and ecstasy in a sample of young
adult nightlife attendees. Psychol Sex. 2018;9(1):54-68. doi:
10.1080/19419899.2018.1425220.
92. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine
pharmacology and central nervous system-mediated effects.
Ochsner J. 2013;13(2):214-23.
93. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The
epidemiology of benzodiazepine misuse: a systematic review.
Drug Alcohol Depend. 2019;200:95-114. doi: 10.1016/j.
drugalcdep.2019.02.033.
94. Fox C, Liu H, Kaye AD, Manchikanti L, Trescot AM, Christo
PJ, et al. Clinical Aspects of Pain Medicine and Interventional
Pain Management: A Comprehensive Review. Antianxiety
agents. Paducah, KY: ASIPP Publishing; 2011. p. 543-52.
95. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter
RA, Bolden-Watson C, et al. Prevalence of sexual
dysfunction among newer antidepressants. J Clin Psychiatry.
2002;63(4):357-66. doi: 10.4088/jcp.v63n0414.
96. Lydiard RB, Howell EF, Laraia MT, Ballenger JC. Sexual side
effects of alprazolam. Am J Psychiatry. 1987;144(2):254-5.
doi: 10.1176/ajp.144.2.254b.
97. Sandeep G, Dheeraj A, Sharma NK, Jhade D, Bharti A. Effect
of plumbagin free alcohol extract of Plumbago zeylanica
Linn. root on reproductive system of female Wistar rats. Asian
Pac J Trop Med. 2011;4(12):978-84. doi: 10.1016/s1995-
7645(11)60230-7.
98. El-Sokkary GH, Hareedy HH, Youns HA. Protective role of
melatonin on the effect of diazepam on proliferative activity,
morphological changes and testosterone levels in the testes of
rats. J Histol Histopathol. 2018;5(5):1-9. doi: 10.7243/2055-
091x-5-5.
99. Shamloul R, Ghanem H. Erectile dysfunction. Lancet.
2013;381(9861):153-65. doi: 10.1016/s0140-6736(12)60520-0.
100. Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM,
Abubakar T, et al. Benzodiazepines: uses, dangers, and
clinical considerations. Neurol Int. 2021;13(4):594-607. doi:
10.3390/neurolint13040059.
101. Substance Abuse and Mental Health Services Administration
(SAMHSA). Substance Use Disorder Treatment for People with
Co-Occurring Disorders. Rockville, MD: SAMHSA; 2020.
102. Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P,
Carvalho M. The hallucinogenic world of tryptamines: an
updated review. Arch Toxicol. 2015;89(8):1151-73. doi:
10.1007/s00204-015-1513-x.
103. Begola MJ, Schillerstrom JE. Hallucinogens and their
therapeutic use: a literature review. J Psychiatr Pract.
2019;25(5):334-46. doi: 10.1097/pra.0000000000000409.
104. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use
disorders. Lancet. 2019;394(10200):781-92. doi: 10.1016/
s0140-6736(19)31775-1.
105. Nicolosi C, Di Leo R, Girlanda P, Messina C, Vita G. Is there
a relationship between somatic and autonomic neuropathies
in chronic alcoholics? J Neurol Sci. 2005;228(1):15-9. doi:
10.1016/j.jns.2004.09.024.
)